XML 81 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)
 1 Months Ended 3 Months Ended 12 Months Ended 24 Months Ended
Sep. 29, 2023
USD ($)
rate
Jul. 06, 2023
USD ($)
Jan. 17, 2023
USD ($)
Mar. 31, 2021
USD ($)
Jan. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Asset Acquisition And Business Combination [Line Items]                      
Other expense, net               $ 28,000,000 $ 35,000,000 $ 373,000,000  
Interest expense, net               1,328,000,000 1,464,000,000 1,426,000,000  
Goodwill           $ 11,183,000,000   11,183,000,000 11,547,000,000 12,457,000,000 $ 12,457,000,000
Trade receivables, net           1,998,000,000   1,998,000,000 1,790,000,000    
Inventories, net           1,544,000,000   1,544,000,000 1,090,000,000    
Property, plant and equipment, net           1,707,000,000   1,707,000,000 1,600,000,000    
Intangible assets, net           6,456,000,000   6,456,000,000 5,800,000,000    
Deferred tax liabilities, net           163,000,000   163,000,000 $ 202,000,000    
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amoun                      
Asset Acquisition And Business Combination [Line Items]                      
Cash proceeds from divestiture       $ 740,000,000              
Impairment of long-lived assets                   26,000,000 210,000,000
Noncash cumulative foreign currency translation loss                     $ 340,000,000
Asset Impairments | Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amoun                      
Asset Acquisition And Business Combination [Line Items]                      
Impairment of long-lived assets             $ 96,000,000     88,000,000  
Other (Income) Expense | Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amoun                      
Asset Acquisition And Business Combination [Line Items]                      
Impairment of long-lived assets                   $ 26,000,000  
Bausch + Lomb | Johnson & Johnson Vision, Blink Product Line Acquisition                      
Asset Acquisition And Business Combination [Line Items]                      
Cash consideration paid, asset acquisition   $ 107,000,000                  
Bausch + Lomb | Paragon Bio Teck Inc. Asset Acquisition and Total Titanium Inc. Business Combination                      
Asset Acquisition And Business Combination [Line Items]                      
Goodwill           5,000,000   5,000,000      
Trade receivables, net           1,000,000   1,000,000      
Inventories, net           1,000,000   1,000,000      
Property, plant and equipment, net           2,000,000   2,000,000      
Intangible assets, net           43,000,000   43,000,000      
Deferred tax liabilities, net           11,000,000   11,000,000      
XIIDRA® And Certain Other Ophthalmology Assets Acquisition | Bausch + Lomb                      
Asset Acquisition And Business Combination [Line Items]                      
Cash consideration paid $ 1,750,000,000                    
Potential future milestone obligations (up to) 750,000,000                    
Consideration transferred 1,753,000,000                    
Contingent consideration, liability $ 3,000,000                    
Measurement period adjustment, intangible assets, net           5,000,000          
Measurement period adjustment, prepaid expenses and other current assets           5,000,000          
Inventory release turnover cycle, favorable contract, term 2 years                    
Inventory released to cost of goods sold $ 20,000,000                    
Revenues since acquisition           106,000,000          
Earnings since acquisition           $ 17,000,000          
Goodwill 23,000,000                    
XIIDRA® And Certain Other Ophthalmology Assets Acquisition | Bausch + Lomb | Acquisition-Related Transaction Costs                      
Asset Acquisition And Business Combination [Line Items]                      
Other expense, net               20,000,000      
XIIDRA® And Certain Other Ophthalmology Assets Acquisition | Bausch + Lomb | Acquisition-Related Finance Costs                      
Asset Acquisition And Business Combination [Line Items]                      
Interest expense, net               $ 16,000,000      
XIIDRA® And Certain Other Ophthalmology Assets Acquisition | Bausch + Lomb | Cash Payable Upon the Achievement of Specified Commercialization and Sales Milestones for Certain Pipeline Products                      
Asset Acquisition And Business Combination [Line Items]                      
Potential future milestone obligations (up to) 475,000,000                    
XIIDRA® And Certain Other Ophthalmology Assets Acquisition | Bausch + Lomb | Cash Payable Upon the Achievement of Specified Sales Milestones                      
Asset Acquisition And Business Combination [Line Items]                      
Potential future milestone obligations (up to) 275,000,000                    
XIIDRA® And Certain Other Ophthalmology Assets Acquisition | Bausch + Lomb | Milestone Payments                      
Asset Acquisition And Business Combination [Line Items]                      
Contingent consideration, liability $ 31,000,000                    
XIIDRA® And Certain Other Ophthalmology Assets Acquisition | Bausch + Lomb | Milestone Payments | Measurement Input, Discount Rate                      
Asset Acquisition And Business Combination [Line Items]                      
Contingent consideration, liability, discount rate | rate 0.11                    
AcuFocus, Inc. Acquisition | Bausch + Lomb                      
Asset Acquisition And Business Combination [Line Items]                      
Cash consideration paid         $ 31,000,000            
Consideration transferred     $ 35,000,000                
Contingent consideration, liability     $ 5,000,000                
Purchase price, repayment term     18 months                
Intangibles, net     $ 28,000,000                
Goodwill     8,000,000                
Other assets     9,000,000                
Liabilities     $ 6,000,000